论文部分内容阅读
美国 Hoffmann-La Roche公司研究人员在使用白细胞介素12（IL-12）治疗癌症的过程中获得了一个意外的收获。这种细胞因子不仅能激活免疫系统,而且似能阻碍恶性血管生成或肿瘤血管形成,这是当前正在研究的最有前途的抗癌方法之一。 Roche公司的研究人员与波士顿儿童医院的医生们共同发现,这种免疫信使除了能促进对恶性肿瘤的免疫攻击外,还能强烈抑制血管生成。此外,还发现这种作用是由γ干扰素（IFN-γ）介导的。儿童医院和Roche公司的科学家在细胞生长因子诱导的角膜血管形成模型中对IL-12进行了试验。在这项试验中IL-12几乎完全终止了新血管生长。
Researchers from Hoffmann-La Roche in the United States have made an unexpected gain in the treatment of cancer using interleukin-12 (IL-12). This cytokine not only activates the immune system but also appears to hinder malignant angiogenesis or tumor angiogenesis, one of the most promising anticancer methods currently under study. Roche researchers and Boston Children’s Hospital doctors found that in addition to immune messengers to promote immunity against malignant tumors, but also strongly inhibit angiogenesis. In addition, this effect was also found to be mediated by interferon gamma (IFN-γ). Children’s Hospital and Roche scientists tested IL-12 in a cell-growth factor-induced corneal angiogenesis model. IL-12 almost completely halted the neovascularization in this experiment.